Literature DB >> 26261020

Small nuclear ribonucleoprotein associated polypeptide N accelerates cell proliferation in pancreatic adenocarcinoma.

Jin Ma1, Zhuo Zhang2, Jiancheng Wang2.   

Abstract

The spliceosome, the large RNA‑protein molecular complex, is crucial for pre‑mRNA splicing. Several antitumor drugs have been found to tightly bind to the components of the spliceosome and mutations in the spliceosome have been reported in several types of cancer. However, the involvement of the spliceosome in pancreatic adenocarcinoma remains unclear. In the present study, small nuclear ribonucleoprotein associated polypeptide N (SNRPN), a key constituent of spliceosomes, was disrupted in BxPC‑3 pancreatic adenocarcinoma cells using lentivirus‑mediated RNA interference (RNAi). It was found that knockdown of SNRPN reduced the proliferation ability of BxPC‑3 cells, as determined by an MTT assay. Furthermore, cell colony formation was impaired in SNRPN depleted adenocarcinoma cells and cell cycle analysis showed that depletion of SNRPN led to S phase cell cycle arrest and apoptosis. These results suggest that SNRPN is a key player in pancreatic adenocarcinoma cell growth, and targeted loss of SNRPN may be a potential therapeutic method for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26261020     DOI: 10.3892/mmr.2015.4208

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  Development of RNA binding proteins expression signature for prognosis prediction in gastric cancer patients.

Authors:  Liqiang Zhou; You Wu; Lin Xin; Qi Zhou; Shihao Li; Yiwu Yuan; Jinliang Wang; Dengzhong Wu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  The autism-related gene SNRPN regulates cortical and spine development via controlling nuclear receptor Nr4a1.

Authors:  Huiping Li; Pingping Zhao; Qiong Xu; Shifang Shan; Chunchun Hu; Zilong Qiu; Xiu Xu
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.